{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:13:24Z","timestamp":1773404004839,"version":"3.50.1"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI117287"],"award-info":[{"award-number":["R01 AI117287"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:p>Human influenza A and B viruses are highly contagious and cause similar illnesses and seasonal epidemics. Currently available antiviral drugs have limited efficacy in humans with compromised immune systems; therefore, alternative strategies for protection are needed. Here, we investigated whether monoclonal antibodies (MAbs) targeting hemagglutinin (HA) and\/or neuraminidase (NA) proteins would protect immunosuppressed mice from severe infections with influenza B virus. Pharmacologically immunosuppressed BALB\/c mice were inoculated with B\/Brisbane\/60\/2008 (BR\/08) influenza virus and were treated with a single dose of 1, 5, or 25\u2009mg\/kg of body weight per day of either an anti-HA MAb (1D2) or an anti-NA MAb (1F2) starting at 24\u2009hours postinoculation (hpi).<\/jats:p>","DOI":"10.1128\/aac.00284-20","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T14:28:11Z","timestamp":1593700091000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus"],"prefix":"10.1128","volume":"64","author":[{"given":"Bindumadhav M.","family":"Marathe","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-2708","authenticated-orcid":false,"given":"Guha","family":"Asthagiri Arunkumar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vogel","sequence":"additional","affiliation":[{"name":"Veterinary Pathology Core, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Noriel Q.","family":"Pascua","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Webby","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-5682","authenticated-orcid":false,"given":"Elena A.","family":"Govorkova","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Influenza (seasonal)","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. 2019. Influenza (seasonal). World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.04.002"},{"key":"e_1_3_3_4_2","volume-title":"FluView: weekly U.S. influenza surveillance report","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. 2019. FluView: weekly U.S. influenza surveillance report. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/flu\/weekly\/index.htm."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-2918"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6803a1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000532"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16477"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1445446"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/504975"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12170"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.214.113"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/509925"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03026"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit725"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2018.1401926"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.69.1.531"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2011.00304.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04704-9"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22307-8"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0678"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14234"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01696-18"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-017-0011-8"},{"key":"e_1_3_3_25_2","volume-title":"Highlights of prescribing information","author":"Food and Drug Administration","year":"2014","unstructured":"Food and Drug Administration. 2014. RAPIVABTM (peramivir injection), for intravenous use. Highlights of prescribing information. Food and Drug Administration, Harrisburg, PA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206426lbl.pdf."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3665"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3166"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.10.021"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07433-z"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2510.190607"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.02.007"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217307"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30253-X"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01154-17"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.04.006"},{"key":"e_1_3_3_36_2","first-page":"A2072","article-title":"Safety and efficacy of the monoclonal antibody VIS410 in a human volunteer challenge model of infection with an H1N1 influenza A virus","volume":"193","author":"Trevejo JM","year":"2016","unstructured":"Trevejo JM, Sloan S, Szetter K, Bedard S, Hay CA. 2016. Safety and efficacy of the monoclonal antibody VIS410 in a human volunteer challenge model of infection with an H1N1 influenza A virus. Am J Resp Crit Care Med 193:A2072.","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.051"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.030"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00928-3"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2013.25"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2017.8"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403014"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0408-4"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01285-13"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3791\/51112"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00957-17"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02281-16"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3791\/54573"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2014.09.003"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.050"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00284-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00284-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:00:46Z","timestamp":1645480846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00284-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["10.1128\/AAC.00284-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00284-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00284-20"}}